A study of LTP001 for healthy people and those with PAH
Part of Lungs & breathing clinical trials.
This study tests an investigational medicine called LTP001 for pulmonary arterial hypertension (PAH). Part A checks safety in healthy volunteers, and Part B tests if it helps people with PAH by improving blood flow in the lungs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a healthy adult (for Part A) or have a confirmed diagnosis of PAH (pulmonary arterial hypertension) (for Part B).
- If you have PAH, your lung artery pressure must be high (measured as PVR ≥400) and you must be on stable doses of standard PAH medicines.
- You need to be able to walk at least 150 meters but no more than 450 meters in 6 minutes (about 1-2 city blocks).
- Women who can get pregnant must use highly effective birth control; men must use condoms during the study and for 24 hours after the last dose.
- You must not have any significant heart or lung conditions (other than PAH) or allergies to the study drug ingredients.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called LAM-001 for people with high blood pressure in the lungs caused by lung scarring. It aims to see if it can improve symptoms and help you feel better.
This study tests a new pill, ROC-101, for people with pulmonary hypertension (high blood pressure in the lungs). It aims to see if the pill can improve symptoms and daily function.
This study tests a new medicine called IKT-001 for people with pulmonary arterial hypertension (PAH). It aims to see if IKT-001 helps improve exercise ability and other symptoms when added to current PAH therapies.
This study tests whether a drug called IKT-001 is safe and effective for people with pulmonary arterial hypertension (high blood pressure in the lungs). You may qualify if you've already completed a previous IKT-001 study.
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
This trial tests an inhaled medication (TPIP) that opens blood vessels in the lungs to help you breathe easier and be more active. It is for people with PAH who are already on stable treatment and have moderate symptoms.
Hear when a new Healthy Volunteers, Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.